Company Filing History:
1 out of 832,843 Years Active: 2023
Title: Innovations of Johannes Yeh in Monoclonal Antibody Development
Introduction
Johannes Yeh is an accomplished inventor based in Billerica, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on creating antibodies that target specific proteins, which can have profound implications for cancer diagnosis and treatment.
Latest Patents
Johannes Yeh holds a patent for a monoclonal antibody directed to FGFR1. This invention relates to antibodies that specifically bind to and neutralize human, macaque, and mouse forms of FGFR1 with high affinity. The patent also encompasses nucleic acids encoding these antibodies, vectors for their expression, and host cells for producing them. Furthermore, the invention highlights the potential use of these antibodies in the diagnosis and treatment of various cancers.
Career Highlights
Throughout his career, Johannes Yeh has demonstrated a commitment to advancing medical science through innovative research. His patent reflects his expertise in antibody development and his dedication to improving therapeutic options for cancer patients.
Collaborations
Johannes has collaborated with notable colleagues, including Christel Iffland and Christina Esdar. These partnerships have likely contributed to the success of his research and the development of his patented technologies.
Conclusion
Johannes Yeh's work in monoclonal antibody development represents a significant advancement in cancer treatment and diagnosis. His innovative approach and dedication to research continue to impact the field positively.